The majority of paediatric Burkitt lymphoma (pBL) patients that relapse will die of disease, but markers for this high-risk subset are unknown. MYC translocations characterize pBL, but additional genetic changes may relate to prognosis and serve as potential biomarkers. We utilized a molecular inversion probe single nucleotide polymorphism assay to perform high resolution, genome-wide copy number analysis on archival formalin-fixed, paraffin-embedded pBL and germline tissues. We identified copy number abnormalities (CNAs) in 18/28 patients (64%) with a total of 62 CNAs that included 32 gains and 30 copy number losses. We identified seven recurrent CNAs including 1q gain (7/28, 25%), 13q gain (3/28, 11%), and 17p loss (4/ 28, 14%). The minimum common amplified region on 13q was at 13q31 and included the MIR17HG (MIR17-92) locus. Samples with this gain had higher levels of MIR17 RNA and showed a tendency for early relapse. Tumourspecific uniparental disomy was identified in 32% of cases and usually was recurrent. These results demonstrate that high-resolution copy number analysis can be performed on archival lymphoma tissue specimens, which has significance for the study of rare diseases.
Burkitt lymphoma (BL) is a malignancy of mature B-cells that occurs at all ages but is more common in children and accounts for one-third of paediatric non-Hodgkin lymphoma cases (Sandlund et al, 1996) . Paediatric BL (pBL) is curable in up to 90% of cases, but the majority of the patients that relapse will die of disease Patte et al, 2007) . Thus there is a need to identify prognostic markers that can be used to stratify patients at the time of diagnosis and direct therapy. Although translocation of the MYC gene is present in nearly all cases, heterogeneity of tumour genomes in the form of additional gene copy number abnormalities (CNAs) may contribute to the clinical heterogeneity in these patients.
Previous studies of pBL using conventional cytogenetics (Poirel et al, 2009 ) and fluorescence in situ hybridization (FISH) (Nelson et al, 2009 ) have identified recurrent genetic abnormalities, including gain of 1q and 13q and loss of 17p, and found that 13q abnormalities are associated with a worse prognosis. Recently, higher resolution genotyping techniques have been applied to BL (not strictly paediatric cases) including comparative genomic hybridization (CGH) (Salaverria et al, 2008) , array CGH (Toujani et al, 2009) , and arraybased high resolution single nucleotide polymorphism (SNP) analysis (Scholtysik et al, 2010) . These studies identified recurrent gains of 1q and loss of 17p affecting subsets of BL patients. To date, the combination of high-resolution genotyping and clinical outcomes has not been reported.
Our study focused strictly on pBL with exclusion of BL patients over the age of 18 years. The overall incidence of pBL is quite low, limiting the numbers of cases at each institution, and fresh frozen tissue that is typically required for high-resolution genetic studies is often not available. Therefore, we applied a newer assay that allowed us to utilize formalin-fixed, paraffin-embedded (FFPE) tissues from the pathology archives going back approximately 15 years. We used a genome-wide, high-resolution molecular inversion probe (MIP) SNP assay to identify copy number gains, copy number losses, and uniparental disomy (UPD) on DNA isolated from FFPE pBL diagnostic biopsy tissues. Gain of 13q and loss of 17p were validated by FISH, and microRNA (miRNA) expression levels were assessed to correlate with MIR17 locus gain on 13q. This represents the first reported high resolution gene copy number analysis performed on lymphoma using FFPE tissues, and we correlate our findings with clinical parameters and outcome available for the majority of the patients. Furthermore, the assessment of germline DNA on most patients enabled us to provide an assessment of UPD in pBL.
Methods
With approval from the University of Utah Institutional Review Board, 27 pBL cases with adequate available diagnostic biopsy tissue were identified. Five additional cases were obtained from Penn State College of Medicine. The morphology and diagnostic immunohistochemistry and flow cytometry were reviewed by two haematopathologists, and cases with increased nuclear pleomorphism, MIB1 < 95%, or BCL2 protein expression were excluded to confirm the diagnosis of BL according to the World Health Organization 2008 guidelines (Swerdlow et al, 2008) . We applied these stringent criteria because it has been demonstrated that, especially in children, cases with a typical BL morphology and immunophenotype uniformly show a 'molecular BL' expression profile (Dave et al, 2006; Hummel et al, 2006; Klapper et al, 2008) . This approach may, however, potentially exclude some cases with a BL gene expression profile but other atypical features.
Full clinical data including age, gender, tumour site, stage, bone marrow involvement, cerebrospinal fluid involvement, therapy group, lactate dehydrogenase (LDH) levels, uric acid levels, and clinical follow-up were obtained from review of medical records for the patients treated at the University of Utah (n = 27), while only gender, age, and tumour location were available on the Penn State cases (n = 5). 26/27 were treated under the Children's Oncology Group (COG) 5961 protocol Patte et al, 2007) and one (BL11) was treated on the high-risk arm of COG 5911 (Cairo et al, 2002) . One patient (BL22) was lost to follow-up after 32 d and was thus excluded from outcomes analysis.
For 29 of the cases, tumour mass or lymph node biopsies were utilized, and corresponding slides were reviewed to select FFPE blocks with at least 80% tumour, optimal fixation, and minimal necrosis. In three cases, the diagnosis was made in a bone marrow specimen, so particle clot sections were utilized to avoid the effects of decalcification: BL16 had 93% tumour cells on aspirate differential and was fixed in B5 rather than formalin; BL32 had 65% tumour cells and was formalin fixed; and BL13 had very scant tissue after cutting and was thus excluded from MIP and polymerase chain reaction (PCR) analysis. Genomic DNA and total RNA were each isolated from a 25 lm thick section using the RecoverAll kit (Applied BioSystems, Foster City, CA, USA).
DNA was quantitated with PicoGreen (Invitrogen, Carlsbad, CA, USA) and submitted for OncoScan FFPE Express (Affymetrix, Santa Clara, CA, USA), a MIP SNP assay, performed at Affymetrix (Wang et al, 2005 (Wang et al, , 2007 Schiffman et al, 2009 Schiffman et al, , 2010 . The data were then analysed using Nexus Copy Number software (Discovery Edition 5.1; Biodiscovery, El Segundo, CA, USA) with NCBI build 36AE1 of the human genome. The SNP-Rank Segmentation Algorithm, a statistically based algorithm similar to the circular binary segmentation (Olshen et al, 2004) , was used in conjunction with quadratic wave correction. This algorithm applies both the copy number value as well as the B-allele frequency to the segmentation. The significance threshold was set at 5AE0 with a minimum of five probes and a maximum contiguous spacing of 1000AE0 kbp to define a segment. Copy number gains and losses were set to 0AE45 and )0AE45 respectively. These settings accommodated the expected heterogeneity of the tumour samples. High gains and big losses indicating greater than a single copy number change were set at 1AE2 and )1AE2 respectively. Gender correction was applied using Nexus control gender settings. The homozygous frequency threshold was set at 0AE95 and the homozygous value threshold was set at 0AE8 with a minimum loss of heterozygosity (LOH) requirement of 500 kb. The heterozygous imbalance threshold was set at 0AE4. Every gain, loss, or LOH call was directly compared to the patient's normal sample (when available), and changes present in the germline in areas of copy number variation were rejected. LOH was considered UPD when not associated with copy number loss. Copy number losses mapping to the IGH@ (14q32.3), IGK@ (2p11.2), and IGL@ (22q11.2) immunoglobulin loci were considered due to normal VDJ recombination and not included. Additional calls were rejected in samples with increased noise when there did not appear to be a definitive shift of the baseline.
Fluorescence in situ hybridization studies were performed on FFPE tissue sections from nine cases. with standard protocols. Following pretreatment, the cells and probes were co-denatured at 80°C for 5 min and incubated overnight at 37°C using the HYBrite TM system (Abbott Molecular). Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI) in Antifade solution (Abbott Molecular), and the slides were analysed using Olympus BX61 and Leica DM6000B fluorescence microscopes. Hybridization signals were assessed in 100-400 interphase nuclei per specimen by two individuals. Abnormal ranges for deletion of 17p13.1 and amplification (3-15 copies) of 13q31.3 were ‡25% and ‡10%, respectively. Images were acquired and archived using the CytoVision Image Analysis System (Genetix, San Jose, CA, USA).
Total RNA was quantitated using a NanoDrop 1000 (Thermo Scientific, Waltham, MA, USA), and cDNA was generated using the TaqMan Ò MicroRNA Reverse Transcription Kit (Applied Biosystems). Quantitative, real-time reverse transcription PCR was performed using the primer-specific TaqMan kit (Applied Biosystems) for MIR17 reverse transcription (Part #4427975, Assay ID# 2308) followed by qPCR with TaqMan Ò Universal PCR Master Mix, No AmpErase Ò UNG (Part #4324018). MiRNA levels were normalized to the expression level of mature miRNA Control RNU6-2 (RNU6B; Part #4427975, Assay ID# 1093). Reactions were performed in triplicate on a Roche LightCycler480, and the results are the mean of two experiments from separate reverse transcription reactions normalized to expression levels from an FFPE spleen specimen. For the assessment of MYC mRNA, cDNA was generated with the High Capacity Reverse Transcription kit (Applied Biosystems). Real-time, quantitative PCR was performed on the Roche LightCycler480 using custom-designed primers (available on request) and the SsoFast TM EvaGreen Ò Supermix (cat#172-5200; Bio-Rad, Hercules, CA, USA). Expression was normalized to HPRT1 and expressed relative to MYC transcript levels from FFPE spleen tissue. Raji and Ramos human BL cell lines were generously provided by Dr Mitchell Cairo, New York University, and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum at 37°C with humidified 5% CO 2 atmosphere.
RNA was isolated using the RNAqueous Ò kit (Applied Biosystems/Ambion) and assayed for MYC mRNA and MIR17 as above. For statistical analysis, pairwise comparisons were made using Fisher's Exact test (for categorical variables) and t-tests (for continuous variables). Survival analysis was performed using the Kaplan-Meier method and log-rank test. Two-tailed P-values are reported, and were considered signficant when <0AE05.
Results

Patient samples and clinical data
Tissue samples were available from 32 pBL patients (Table I) . Patients included 25 males and seven females (M:F ratio 3AE6) with a mean age of 7AE5 years (range 2-18). At presentation, LDH ranged from 443 to 13 851 u/l (median 2751) and uric acid from 89 to 1909 lmol/l (median 327). Patients were Murphy stage I (n = 1), II (n = 9), III (n = 13), and IV (n = 4) and included 1 Group A patient and 4 Group C patients (marrow positive with >25% tumour cells); the remainder were Group B. No patients had cerebrospinal fluid disease. Outcomes data were available for 26 patients with a median follow-up of 32AE7 months. A total of three patients relapsed (one stage II patient and two stage III patients) and three died (the two stage III patients that relapsed and a different stage II patient who did not have a complete clinical response). Neither relapse nor survival was significantly associated with stage, therapy group, or LDH greater than twice the upper limit of normal, which may be due to the small sample size.
Twenty-eight of the 32 tumour samples had adequate tumour tissue and DNA for analysis. BL7 and BL13 were excluded from MIP and PCR analysis when deeper sections revealed a lack of tumour. BL27 and BL31 were excluded from MIP analysis due to poor DNA yields. Negative bone marrows were available for 26 patients, and 24 yielded adequate DNA for MIP analysis (BL11 and BL12 yielded insufficient germline DNA for analysis).
MIP SNP assay
We identified a total of 62 CNAs (defined as change seen in the same cytoband in one or more patients) unique to the tumour genome, which included 32 gains and 30 copy number losses (Fig 1; all CNAs and UPD events for each case are listed in Table S1 ). 18/28 cases (64%) had at least one gain or loss. Six cases had a single gain or loss, five cases had two, and seven cases had three or more copy number changes. The mean number of gains and losses per case were 1AE2 and 1AE1, respectively (median 1AE0 and 1AE0).
In addition, regions of UPD (copy-neutral LOH) were identified in nine cases (32%) including one case with three UPD segments, three cases with two segments, and five cases with a single UPD segment. UPD segments were often large, involving half or more of the chromosomal arm with a median length of 40AE6 MB (range 8AE1-99AE3). Regions with recurrent UPD included 1p (n = 4), 1q (n = 2), 6p (n = 2), 17p (n = 3), and 17q (n = 2). The only region of UPD that did not occur in more than one sample involved nearly the entire p arm of 
Recurrent CNAs
We identified seven recurrent CNAs (same cytoband affected in two or more patients), which included two gains and five losses (Table II) . We found gains of 1q in 7/28 patients (25%) and gains of 13q in three (11%). Recurrent copy number losses were identified on 17p (n = 4, 14%), 13q (n = 2, 7%), 14q (n = 2, 7%), Xp22.33 (n = 3, 11%), and Xp21.3 (n = 2, 7%).
The gains on chromosome 1q were generally large, involving almost the entire q arm in three cases (Fig 2A) . A minimum common region (MCR) defined by a relatively short 1q gain in BL25 included 7AE0 MB localized to cytobands q21.1-q21.3. However, if this case is ignored, there is a much larger MCR of 48AE6 MB from q21.1 to q31.2.
The losses on 17p showed a 4AE0 MB MCR from p13.1 to p12 that included 20 genes (Fig 2B) . Although this MCR does not include TP53, the losses on three of the four cases did include TP53. FISH for the 17p13.1 locus was performed on nine cases including three that showed deletion by MIP and six that did not. The three deleted cases were confirmed by FISH while 5/6 negative for copy loss by MIP were negative by FISH. One case was FISH positive (mildly above threshold at 34%) that did not show deletion by MIP. This suggests the possibility of a small tumour subclone in the region where FISH scoring was performed and demonstrates how FISH may detect focal abnormalities that average out copy number across the entire tissue section. Dilution with non-tumour DNA is not likely the cause as other integer copy number changes were distinctly identified at other loci in this sample.
Gain of 13q was identified in 3/28 patients (11%) with a 4AE7 MB MCR that includes three genes and eight miRNAs: 
The event column shows relapse and/or death with the total months of follow up. *Samples excluded from MIP analysis due to insufficient tissue (BL13), insufficient DNA (BL27 and BL31) or lack of tumour in deeper sections (BL7). BL14 was excluded up front as the morphology was most consistent with diffuse large B-cell lymphoma. Patient BL22 was excluded from survival analysis due to a very short time before the patient was lost to follow-up.
GPC5, GPC6, LINC00410, MIR622, and the MIR17HG gene encoding the MIR17-92 cassette of seven miRNAs (Fig 2C) . Interestingly, two of these cases showed high gains in excess of five copies (Fig 1D) . Gain of 13q31 was verified by FISH in all three cases, and no gain was seen in the additional six cases that lacked this gain by MIP. Although the number of patients is small, those with 13q31 gain were more likely to have relapsed over a minimum follow-up period of 6AE5 months (2/3 with 13q31 gain relapsed vs. 1/24, P = 0AE025). When formal Kaplan-Meier analysis was performed, the association between 13q31 gain and relapse was not statistically significant (P = 0AE19), most likely due to lack of statistical power. There was no significant relationship between 13q31 gain and stage, therapy group, serum LDH concentration greater than twice the upper limit of normal, or overall survival (P = 0AE25). The patients with gain of 13q31 were also more likely to have loss of 17p with TP53 deletion (2/3 with 13q31 gain had TP53 deletion vs. 1/25 without 13q31 gain, P = 0AE023). The association was stronger when patients with TP53 UPD were included: 3/3 with 3q31 gain had TP53 deletion or UPD vs. 3/ 25 without 13q31 gain (P = 0AE0061). However, TP53 deletion and UPD, either alone or in combination, did not significantly correlate with either relapse (P = 0AE71) or survival (P = 0AE75). The gain of 13q31 was not significantly associated with any other copy number changes; however, the three samples with 13q31 also showed the highest total numbers of copy number and/or UPD events (BL4, n = 10; BL10, n = 8; BL25, n = 8; Table S1 ). This raises the possibility that 13q31 gain is a marker of overall complexity and that increased genomic changes influence prognosis, but other samples with frequent changes (BL3, n = 7; BL16, n = 6; BL19, n = 8) showed neither 13q31 gain nor clinical events.
MiRNA expression
To examine the effect of 13q31 gain on miRNA expression, we determined the relative expression levels of MIR17 RNA in all samples (Fig 3A) . The samples with 13q31 gain showed higher expression of MIR17 (mean relative expression of 31AE9 in samples with gain vs. 11AE7 in those without gain, P = 0AE043; Fig 3B) . Two additional samples (BL8 and BL26) showed high MIR17 levels in the absence of a 13q31 gain suggesting that there are other mechanisms that can lead to increased expression. Because MIR17HG is a MYC target (O'Donnell et al, 2005), we analysed all samples for relative levels of MYC transcript expression. Relative MYC transcript levels varied from 0AE7 to 27AE6 (median 8AE3) relative to a reactive lymph node control, but MYC levels were not elevated the samples with high MIR17, and MIR17 expression showed a slight negative correlation with MYC expression (regression slope = )0AE4, R 2 = 0AE05; Fig 4) . For comparison, we also assayed relative MYC and MIR17 in two BL cell lines. The BL cell lines Raji and Ramos showed modestly increased relative MYC transcript levels (9AE7 and 16AE6, respectively) with marked relative increases in MIR17 miRNA (63AE5 and 150AE8, respectively). The very high levels of MIR17 miRNA in the Ramos cells may be related to 13q31 amplification described previously (Karpova et al, 2006) .
Non-recurrent CNAs
Other notable gains and losses were detected in our cohort but were non-recurrent. One patient, BL1, demonstrated a 400 kb hemizygous deletion of the SH2D1A gene at Xq25 in both his tumour and germline DNA, which is diagnostic of X-linked lymphoproliferative disease (XLP). XLP patients are at an approximately 200-fold increased risk for lymphoma, and BL accounts for approximately half of the lymphomas in these patients (Nagy & Klein, 2010) . This SH2D1A deletion may thus represent the cause of this patient's pBL. Deletion of the tumour suppressor gene FHIT, which has previously been described in BL (O'Donnell et al, 2005; Scholtysik et al, 2010) , was seen in a single patient (BL4) and was the only gene in the deleted segment. One patient (BL10) demonstrated a high gain of 8q that included the MYC locus. Finally, a homozygous 9p21 loss including the MTAP, CDKN2A, and CDKN2B genes was noted in the pBL tumour of a single patient, while UPD involving the CDKN1A locus on 6p21 was identified in tumours from two additional patients. BL9  BL1  BL12  BL28  BL20  BL7  BL16  BL29  BL30  BL23  BL17  BL2  BL31  BL15  BL18  BL11  BL24  BL21  BL3  BL19  BL6  BL22  BL27  BL10  BL25  BL26  BL8 
Discussion
We report the first high-resolution (330k) genome-wide copy number analysis of lymphoma performed using FFPE archival tissues. We identified 32 gains and 30 copy number losses with at least one gain or loss in 64% of our samples. Recurrent CNAs were relatively few in number and included two gains and five losses. The incidence of genetic changes is similar to data reported from CGH studies including one study that found aberrant CGH profiles in 17/26 (65%) of classic BL (Salaverria et al, 2008) and one that found CNAs in 7/13 patient samples (Toujani et al, 2009) . A recent high-resolution SNP analysis of 39 frozen BL samples found a total of 308 gains and 220 losses, which probably reflects both higher resolution and a larger number of cases than our current study (Scholtysik et al, 2010) ; this may also reflect the variability of results found when using different copy number calling algorithms in different studies.
The CNAs reported in this study, in particular the recurrent gain of 1q, gain of 13q, and loss of 17p, compare well with what has been described previously by conventional cytogenetics (Lones et al, 2004; Poirel et al, 2009) , FISH (Nelson et al, 2009) , aCGH (Tagawa et al, 2007; Toujani et al, 2009) , high resolution SNP array (Scholtysik et al, 2010) , and SNP array analysis of human immunodeficiency virus-related Burkitt lymphoma (Capello et al, 2009) . Our findings are largely in agreement with the only other high-resolution SNP array study (Scholtysik et al, 2010) , which showed gains on 1q localized to MCRs at 1q21.1 (26%) and 1q31.3 (33%). They also described 13q31 gain in 18% of samples and 17p13.1 loss in 18%. The recurrent losses we identified at 13q33.1-q34 and Xp22.33 overlap with recurrent MCRs reported in their study, and several non-recurrent gains (4/14) and losses (4/13) that we identified were noted by Scholtysik et al (2010) . Several recurrent gains reported by Scholtysik et al (2010) that did not occur in our data set include 3q27.3 (BLC6, 7/39 samples), 6q15 (7/39), and 7p12.2 (IKZF1, 6/ 39). Of interest, they noted a gain on 18q21.2 in 3/39 cases that included the POLI gene and seemed to correlate with increased numbers of CNAs. Although we observed a gain of this region in only one case (BL4), this case did have the largest number of CNAs (six gains and four losses) of any tumour in our study. Overall, the similarities between our findings and previous reports demonstrate the validity of our approach using MIP technology on FFPE specimens.
The MIR17HG cluster is oncogenic and has been shown to accelerate lymphoma development in a mouse model (He et al, 2005) and increase tumourigenicity in cooperation with MYC (Tagawa et al, 2007) . In addition, expression is increased in lung carcinoma (Hayashita et al, 2005) and in colorectal adenoma to adenocarcinoma progression (Diosdado et al, 2009 ) with increased expression linked to both copy number gains in a subset of cases. Increased MIR17HG expression has also been shown in mantle cell lymphoma Navarro et al, 2009 ) and BL (Tagawa et al, 2007) , and again increased expression was related to copy number changes in some but not all cases. We report a correlation of MIR17 miRNA expression with CN gain in pBL, which is similar to the results of a previous study that found increased expression of the MIR17HG cluster in four BL cases with a 13q31.2 amplification by FISH (Robertus et al, 2010) . However, additional cases had high level expression of MIR17 in the absence of 13q31 gain. Although MIR17HG has been established as a MYC transactivation target in a B-cell line model (O'Donnell et al, 2005) and MIR17HG expression correlates positively with MYC expression in colorectal tumours (Diosdado et al, 2009 ), we were unable to demonstrate a positive association between MIR17 expression and increased MYC mRNA in our patient samples. In addition, the MIR17 levels were markedly increased in the presence of only modest increases in MYC transcripts in two BL cell lines.
We noted a strong correlation between 13q31 gain and loss or UPD on 17p13 that included the TP53 locus. It is conceivable that the predicted anti-apoptotic effects of MIR17HG via targeting PTEN and E2F1 (Hammond, 2006) could synergize with the loss of TP53 function to strongly shift the balance away from apoptosis and towards proliferation in MYC-driven tumours. As TP53 is frequently altered in BL (Gaidano et al, 1991) , the gain of 13q31 in a smaller subset could lead to more aggressive tumour behaviour. The significance of the association between 13q31 gain and 17p13 loss/ UPD merits further investigation and should be confirmed in a larger sample of pBL patients.
Areas of UPD have previously been described in BL (Scholtysik et al, 2010) and involve the same chromosome arms as the regions of recurrent UPD in our study: 1p, 1q, 6p, 17p, and 17q. Our study has the advantage of comparison to germline DNA to verify that the UPD events are unique to the tumour genome. The role of these regions of UPD in the pathogenesis of pBL remains to be determined, but the fact that the UPDs tended to be recurrent and that they encompass genes including CDKN1A and TP53 suggest that they may be significant. UPD on 17p correlates with the presence of TP53 mutations in mantle cell lymphoma ), and we have found overexpression of TP53 protein in cases with TP53 copy loss or UPD, suggesting TP53 mutation (Leventaki et al, 2011; Mod Pathol 23:306A, abstract; manuscript in preparation) . UPD has also been described in follicular lymphoma, where UPD of chromosome 1p is associated with a worse prognosis and UPD of 16p is associated with transformation (O'Shea et al, 2009) . Further study will be required to evaluate the role of UPD in the pathogenesis and prognostication of pBL.
In summary, we report the first high-resolution gene copy number and UPD analysis performed on lymphoma using FFPE tissues. The results of our analysis on pBL FFPE tissues show strong agreement with previous aCGH and SNP array studies performed on frozen BL tissue specimens. In our pBL cohort, gain of 13q31 occurred in 11% and was associated with increased expression of MIR17. Although not significantly related to relapse or overall survival by Kaplan-Meier analysis, the categorical association between 13q31 gain and early relapse indicates that further studies in a larger sample set should be performed to assess possible relationships with patient outcomes. Analysis on FFPE greatly expands the ability to perform detailed genetic analysis, which was previously only possible on fresh or frozen tissue samples that are often not available. This approach 'unlocks' the FFPE archives and is particularly advantageous for the genomic analysis of rare tumour specimens.
